When machine learning models enter regulated medical hardware, static premarket validation is obsolete. Governed by FDA Good Machine Learning Practice (GMLP), Predetermined Change Control Plans (PCCP), and the European Union Artificial Intelligence Act, medical AI demands continuous dataset provenance, algorithmic bias auditing, and real-time inference drift surveillance.
The integration of artificial intelligence and machine learning into medical software (Software in a Medical Device — SiMD, or Software as a Medical Device — SaMD) introduces a fundamental engineering paradox. Traditional medical device quality systems (21 CFR Part 820 / ISO 13485) are predicated upon frozen, deterministic specifications. Machine learning models, conversely, are data-dependent systems that degrade when deployed across shifting clinical populations (covariate shift) or when sensor hardware parameters drift.
To resolve this tension, international regulatory bodies have established three interlocking pillars:
Jointly published by the US FDA, Health Canada, and the UK MHRA, the 10 Guiding Principles for Good Machine Learning Practice define the gold standard for medical AI. Key mandates include ensuring that training datasets represent the intended patient population, that models are engineered with clinical team involvement, that testing demonstrates statistical independence from training sets, and that human-in-the-loop interpretability is maintained.
Authorized under Section 3308 of the Food and Drug Omnibus Reform Act of 2022 (FDORA), an FDA Predetermined Change Control Plan empowers manufacturers to pre-specify future algorithm retraining cycles, feature engineering enhancements, and performance boundaries within the original marketing authorization (e.g., 510(k) or De Novo).
So long as post-market model updates conform strictly to the pre-approved Modification Protocol and remain within the quantified Acceptance Criteria Envelope, the manufacturer may deploy refined model weights without submitting a new premarket notification. If an update breaches the envelope, PMX OS flags a mandatory requirement for a new 510(k) submission.
Under Regulation (EU) 2024/1689 (the EU AI Act), AI systems intended to be used as safety components of medical devices governed by the EU MDR (2017/745) are automatically classified as High-Risk AI Systems (Annex III / Article 6). This triggers legal obligations including: continuous risk management systems (Article 9), high-quality training and validation datasets with bias examination (Article 10), automated event logging for post-market traceability (Article 12), and robust human oversight interfaces (Article 14).
| PCCP Dimension | Pre-Authorized Acceptance Envelope | RespiraAI v4.2 Status | Automated Guardrail |
|---|---|---|---|
| Sensitivity Floor | ≥ 92.0% on held-out test sets | 94.8% | Auto-blocks deployment if sensitivity < 92.0% |
| Demographic Parity | Max variance ±3.0% across skin phototypes | ±1.8% | Triggers ethics review if parity delta > 3.0% |
| Inference Latency | ≤ 45ms per window on MCU | 28ms | Hardware timer interrupt kills runaway inference |
| Data Drift Metric | KS statistic ≤ 0.050 vs baseline | 0.038 | Alerts clinical team to re-calibrate baseline |
Approved modification protocol allows periodic retraining of RespiraAI on ambulatory continuous biometric data collected through PMCF registry CS-088.
Full transparency into dataset lineage, demographic representation, ROC validation metrics, and live post-market covariate drift monitoring.
42,500 patient-hours collected across 4 clinical partner institutions. Filtered for signal noise and motion artifacts.
Sensitivity audited across all 6 skin phototypes. Maximum divergence is 1.8%, satisfying GMLP demographic equity guidelines.
Continuous evaluation on anonymized telemetry windows. Distribution shifts remain well under the 0.050 alert boundary.
| Cohort Segment | Patient Hours | Sensitivity (95% CI) | Specificity | PPV | NPV | GMLP Equity Status |
|---|---|---|---|---|---|---|
| Fitzpatrick Phototype I – II | 14,200 hrs | 94.9% (93.1 – 96.2%) | 97.4% | 91.8% | 98.4% | Pass (Δ +0.1%) |
| Fitzpatrick Phototype III – IV | 16,100 hrs | 95.3% (93.8 – 96.6%) | 97.6% | 92.1% | 98.6% | Pass (Δ +0.5%) |
| Fitzpatrick Phototype V – VI | 12,200 hrs | 94.1% (92.3 – 95.7%) | 96.8% | 90.3% | 98.0% | Pass (Δ -0.7%) |
| Biological Sex: Female | 20,900 hrs | 94.7% (93.0 – 96.0%) | 97.1% | 91.2% | 98.2% | Equitable (Δ -0.1%) |
| Biological Sex: Male | 21,600 hrs | 94.9% (93.3 – 96.3%) | 97.3% | 91.6% | 98.3% | Equitable (Δ +0.1%) |
Simulate a proposed model update (e.g. RespiraAI v4.3 retrained with Sensor S-22 telemetry). Adjust model sensitivity and memory footprint to test whether the change qualifies under your approved PCCP or triggers a mandatory 510(k).
Proposed parameters satisfy all pre-authorized criteria under FDA 510(k) K240982 PCCP-01. The model update may be compiled and distributed via Firmware 3.8.2 without a supplemental 510(k) filing.